Optimal Medical Management of Atherosclerotic Intracranial Stenosis
Stroke · 2024-02 · 55 (2) · 335-343
DOI: 10.1161/strokeaha.123.043633 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stroke, 2024-02. Verfasst von Ashley M Wabnitz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of South Carolina, Charleston. Hauptthemen laut MEDLINE: Stroke, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
Reducing the high risk of recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis (sICAS) has proven to be challenging, but aggressive medical management, with intensive risk factor control and antithrombotic therapy, has been shown to be beneficial. High-intensity statins are recommended for patients with atherosclerotic stroke, including sICAS. Ezetimibe and PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors are beneficial for those who fail to reach low-density lipoprotein targets or those with statin intolerance. The treatment target for sICAS is low-density lipoprotein
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Medical University of South Carolina, Charleston.
ORCID-Profile: Ashley M Wabnitz, Tanya N Turan
Zitieren
APA
Wabnitz, A. M., & Turan, T. N. (2024). Optimal Medical Management of Atherosclerotic Intracranial Stenosis. Stroke, 55(2), 335-343. https://doi.org/10.1161/strokeaha.123.043633
Vancouver
Wabnitz AM, Turan TN. Optimal Medical Management of Atherosclerotic Intracranial Stenosis. Stroke. 2024;55(2):335-343. doi:10.1161/strokeaha.123.043633
BibTeX
@article{Wabnitz2024,
author = {Wabnitz, Ashley M and Turan, Tanya N},
title = {Optimal Medical Management of Atherosclerotic Intracranial Stenosis},
journal = {Stroke},
year = {2024},
volume = {55},
number = {2},
pages = {335--343},
doi = {10.1161/strokeaha.123.043633}
}
EUVIMED